Boston Scientific Announces FDA Approval and U.S. Launch of ION Platinum Chromium Stent System (BSX)

Boston Scientific Corporation BSX today announced U.S. Food and Drug Administration approval and launch of the ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System, the Company's third-generation drug-eluting stent technology. The ION Stent System incorporates a unique platinum chromium alloy designed specifically for coronary stenting and intended to improve the acute performance of coronary stent implantation in the treatment of coronary artery disease.